3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
26
Lymphoma, Mantle-Cell
18
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Waldenstrom Macroglobulinemia
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, B-Cell
3
Pancreatic Neoplasms
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Ovarian Neoplasms
1
Neuritis
1
Neoplasm, Residual
1
Lymphoproliferative Disorders
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Hematologic Neoplasms
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anemia, Hemolytic, Autoimmune
1
Interventions
pembrolizumab
31
Gemcitabine
26
Nivolumab
20
atezolizumab
16
Cisplatin
15
avelumab
14
Carboplatin
12
Docetaxel
10
enfortumab vedotin
8
Magnetic Resonance Spectroscopy
8
durvalumab
7
Specimen Handling
7
Paclitaxel
7
Ipilimumab
6
toripalimab
5
pemigatinib
5
cabozantinib
5
vinflunine
4
sacituzumab govitecan
4
Taxes
4
Pemetrexed
4
tislelizumab
3
cabazitaxel
3
Standard of Care
3
Mitomycin
3
Injections
3
Everolimus
3
Albumin-Bound Paclitaxel
3
sapanisertib
2
olaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Transitional Cell
×
acalabrutinib
×
Clear all
NCT02351739
2019-09-10
KEYNOTE143
Acerta Pharma BV
Phase 2
Completed
78 enrolled
10 charts